Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NVNO 
enVVeno Medical Corp (NVNO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NVNO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.43% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.75M USD | Price to earnings Ratio - | 1Y Target Price 12.5 |
Price to earnings Ratio - | 1Y Target Price 12.5 | ||
Volume (30-day avg) 1 | Beta 1.01 | 52 Weeks Range 0.77 - 5.70 | Updated Date 08/29/2025 |
52 Weeks Range 0.77 - 5.70 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.59% | Return on Equity (TTM) -64.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -17511138 | Price to Sales(TTM) - |
Enterprise Value -17511138 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.87 | Shares Outstanding 19247100 | Shares Floating 17800526 |
Shares Outstanding 19247100 | Shares Floating 17800526 | ||
Percent Insiders 0.84 | Percent Institutions 27.28 |
Upturn AI SWOT
enVVeno Medical Corp
Company Overview
History and Background
enVVeno Medical Corp is a medical technology company focused on developing and commercializing innovative solutions for the treatment of chronic venous disease. Formerly known as NanoVasc, Inc., the company changed its name to enVVeno Medical Corp. The company is still emerging and actively developing their technology with the goal of entering the broader market
Core Business Areas
- Venous Disease Treatment: Developing and commercializing bioprosthetic valve technology for the treatment of chronic venous disease.
Leadership and Structure
Details of the company's leadership team and organizational structure are limited and not widely published in a structured form. Investor relations information will contain this.
Top Products and Market Share
Key Offerings
- enVVe Bioprosthetic Valve: A bioprosthetic valve designed to improve venous valve function in patients with chronic venous disease. Currently this is still a pipeline product, and has not been launched. Competitors will include companies providing treatments for CVD
Market Dynamics
Industry Overview
The market for venous disease treatment is growing due to aging populations and increasing prevalence of conditions like chronic venous insufficiency. This market includes surgical, endovascular, and medical therapies.
Positioning
enVVeno Medical Corp is positioned as an innovator in the venous disease treatment market with its bioprosthetic valve technology, targeting unmet needs in venous valve repair.
Total Addressable Market (TAM)
The TAM for venous disease treatment is estimated to be billions of dollars annually, encompassing various treatment modalities. The exact positioning depends on clinical trial outcomes and regulatory approvals. Unknown TAM value.
Upturn SWOT Analysis
Strengths
- Innovative bioprosthetic valve technology
- Focus on unmet needs in venous disease treatment
- Potential for improved patient outcomes
Weaknesses
- Limited commercialization experience
- Reliance on successful clinical trial outcomes
- Need for regulatory approvals
Opportunities
- Expanding venous disease treatment market
- Potential for partnerships and collaborations
- Growing awareness of venous disease
Threats
- Competition from established players
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
Competitive Landscape
The company faces competition from established medical device companies and pharmaceutical companies in the venous disease treatment market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercialization of its bioprosthetic valve. Analyst projections are not available.
Recent Initiatives: Focus on clinical trials and regulatory submissions for their bioprosthetic valve. Building up infrastructure to scale.
Summary
enVVeno Medical Corp is a developing med-tech company focused on creating innovative venous disease solutions. The company is still in early stages, relying heavily on clinical trial success and regulatory approval to enter market. enVVeno's innovative bioprosthetic valve technology holds promise, but also needs to navigate competition to achieve market share. It needs to focus on successful clinical trials, and securing regulatory approval to move forward.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Press releases
- Industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. The information provided is based on publicly available data and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About enVVeno Medical Corp
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2018-05-31 | CEO & Director Mr. Robert A. Berman | ||
Sector Healthcare | Industry Medical Devices | Full time employees 37 | Website https://www.envveno.com |
Full time employees 37 | Website https://www.envveno.com | ||
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.